J Korean Med Assoc.  2003 Aug;46(8):729-740. 10.5124/jkma.2003.46.8.729.

Pancreatic Cancer

• Song SY

• KMID: 2183113
• DOI: http://doi.org/10.5124/jkma.2003.46.8.729

Abstract

Pancreatic ductal adenocarcinoma is the fourth to fifth leading cause of cancer death in the Western hemisphere with a median survival of less than 6 months. This highly aggressive cancer is characterized by invasive biology, rapid progression and profound resistance to treatment. Most pancreatic cancers are already unresectable at the time of diagnosis. Also, for the patients who undergo potentially curative resection, the 5-year survival is only 10~20%. Recently, the incidence of this fatal cancer has been increased remarkably in our country. It is time to start having a serious considerations to pancreatic cancer. Over the past few decades, a lot of trials were performed to improve survival and symptoms in patients with pancreatic cancer, and some improvements occur in patients who also receive chemotherapy and/or radiotherapy. But the impact on long-term survival has been minimal owing to the intense resistance to all extant treatments. Advances in pathological classification and cancer genetics have improved our descriptive understanding of this disease; however, important aspects of pancreatic cancer biology remain poorly understood. Factors associated with an increased risk of pancreatic cancer include smoking, chronic pancreatitis, diabetes, prior gastric surgery, and exposure to radiation or chemicals such as chlorinated hydrocarbon solvents. A number of syndromes are identified with an increased incidence of pancreatic cancer. Surgical operation has been the dominant procedure for treating pancreatic cancer. But, it is notoriously difficult to detect at its initial condition, and most pancreatic cancers are already unresectable at the time of diagnosis. Until now, gemcitabine has been established as a new standard for the treatment of unresectable pancreatic cancer in terms of clinical benefit response, time to progression, and survival. However their effects were modest. Advancement in the understanding of the biology of pancreatic cancer has helped identify several molecular targets for the development of novel therapies. Gene therapy and immunotherapy are currently in the spotlight as promising new methods for cancer cure. Many studies have revealed the potential of their therapy for the treatment of pancreatic cancer, and early clinical trials are taking place to evaluate the success of each therapy. A better understanding of pancreatic cancer biology will lead the way to more effective treatments, however, we should keep in mind that the single most important factor to improve the survival of pancreatic cancer patient is the early diagnosis in a radically resectable condition.

Keyword

Pancreatic cancer; Early diagnosis; Treatment

MeSH Terms

Adenocarcinoma
Biology
Classification
Diagnosis
Drug Therapy
Early Diagnosis
Genetic Therapy
Genetics
Humans
Immunotherapy
Incidence
Pancreatic Ducts
Pancreatic Neoplasms*
Pancreatitis, Chronic
Radiotherapy
Smoke
Smoking
Solvents
Smoke
Solvents

Reference

1. Tsuchiya R, Tsunoda T. Tumor size as a predictive factor. Int J Pancreatol. 1990. 7:117.

2. Satake K, Nishiwaki H, Yokomatsu H. Surgical curability and prognosis : standard resection versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet. 1992. 175:259.

4. Yamamoto M, Ohashi O, Saitoh Y. Japan pancreatic cancer resistry : Current status. Pancreas. 1998. 16:238–242.

5. Demeure MJ, Doffek KM, Komorowski RA, Wilson SD. Adenocarcinoma of the pancreas : detection of occult metastases in regional lymph nodes by a polymerase chain reaction-based assay. Cancer. 1998. 83:1328–1334.

6. Ariyama J, Suyama M, Satoh K, Sai J. Imaging of small pancreatic ductal adenocarcinoma. Pancreas. 1998. 16:396–401.

7. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Pancreas. 1992. 7:66–86.

8. Lynch HT. Genetics and pancreatic cancer. Arch Surg. 1994. 129:266–268.

9. Lynch HT, Fusaro L, Lynch JF. Familial pancreatic cancer. A family study. Pancreas. 1992. 7:511–511.

10. Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology. 1952. 21:54–63.

11. Ekbom A, McLaughlin JK, Karlsson B, Nyren O, Gridley G, Fraumeri JF, et al. Pancreatitis and pancreatic cancer: A population-based study. J Natl Cancer Inst. 1994. 86:625–627.

12. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, DiFrancesco V, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993. 328:1433–1437.

13. McKusick VA. Mendelian inheritance in man. 1990. Baltimore: Johns Hopkins University Press.

14. Satake K, Takeuchi T, Homma T, et al. Ca 19-9 as a screening and diagnostic tool in symptomatic patients : The Japanese experience. Pancreas. 1994. 9:703–706.

15. Matsumoto S, Harada H, Tanaka J, Ochi K, Seno T, Kunichika K, et al. Evaluation of cytology and tumor markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages. Pancreas. 1994. 9:741–747.

16. Bang SM, Chung HW, Park SW, Chung JB, Kang JK, Song SY, et al. The usefulness of 18 FDG-PET scan in determination of treatment response in pancreatic cancer. Gastroenterology. 2003. 124:Suppl 1. A–188.

17. Burris HA 3rd, Moore MJ, Andersen J, Green HR, Rothenberg ML, Van Hoty DD, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol. 1997. 15:2403–2413.

18. Chung HW, Park JY, Kim SA, Shin Y, Park SW, Song SY, et al. Comparison of concurrent chemoradiation between paclitaxel/furtulon and gemcitabine/furtulon for the locally advanced pancreatic carcinoma. Gastroenterology. 2002. 122:Suppl 1. A–337.